MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32
- PMID: 23339462
- PMCID: PMC3706900
- DOI: 10.1186/gm406
MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32
Abstract
Background: Although microRNAs (miRNAs) are implicated in osteosarcoma biology and chemoresponse, miRNA prognostic models are still needed, particularly because prognosis is imperfectly correlated with chemoresponse. Formalin-fixed, paraffin-embedded tissue is a necessary resource for biomarker studies in this malignancy with limited frozen tissue availability.
Methods: We performed miRNA and mRNA microarray formalin-fixed, paraffin-embedded assays in 65 osteosarcoma biopsy and 26 paired post-chemotherapy resection specimens and used the only publicly available miRNA dataset, generated independently by another group, to externally validate our strongest findings (n = 29). We used supervised principal components analysis and logistic regression for survival and chemoresponse, and miRNA activity and target gene set analysis to study miRNA regulatory activity.
Results: Several miRNA-based models with as few as five miRNAs were prognostic independently of pathologically assessed chemoresponse (median recurrence-free survival: 59 months versus not-yet-reached; adjusted hazards ratio = 2.90; P = 0.036). The independent dataset supported the reproducibility of recurrence and survival findings. The prognostic value of the profile was independent of confounding by known prognostic variables, including chemoresponse, tumor location and metastasis at diagnosis. Model performance improved when chemoresponse was added as a covariate (median recurrence-free survival: 59 months versus not-yet-reached; hazard ratio = 3.91; P = 0.002). Most prognostic miRNAs were located at 14q32 - a locus already linked to osteosarcoma - and their gene targets display deregulation patterns associated with outcome. We also identified miRNA profiles predictive of chemoresponse (75% to 80% accuracy), which did not overlap with prognostic profiles.
Conclusions: Formalin-fixed, paraffin-embedded tissue-derived miRNA patterns are a powerful prognostic tool for risk-stratified osteosarcoma management strategies. Combined miRNA and mRNA analysis supports a possible role of the 14q32 locus in osteosarcoma progression and outcome. Our study creates a paradigm for formalin-fixed, paraffin-embedded-based miRNA biomarker studies in cancer.
Figures




Similar articles
-
An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets.J Hematol Oncol. 2017 May 15;10(1):107. doi: 10.1186/s13045-017-0465-4. J Hematol Oncol. 2017. PMID: 28506242 Free PMC article.
-
A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeutics.medRxiv [Preprint]. 2024 Jun 20:2024.06.19.24309087. doi: 10.1101/2024.06.19.24309087. medRxiv. 2024. PMID: 38946948 Free PMC article. Preprint.
-
Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Epub 2013 Nov 13. Lancet Oncol. 2013. PMID: 24239208
-
Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis.Front Genet. 2020 Aug 11;11:789. doi: 10.3389/fgene.2020.00789. eCollection 2020. Front Genet. 2020. PMID: 32849795 Free PMC article.
-
Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma.BJU Int. 2014 May;113(5):813-21. doi: 10.1111/bju.12551. BJU Int. 2014. PMID: 24180461 Review.
Cited by
-
Predicting prognosis and immune status in sarcomas by identifying necroptosis-related lncRNAs.Aging (Albany NY). 2024 Jan 8;16(1):493-517. doi: 10.18632/aging.205383. Epub 2024 Jan 8. Aging (Albany NY). 2024. PMID: 38194709 Free PMC article.
-
Dysregulated m6A-Related Regulators Are Associated With Tumor Metastasis and Poor Prognosis in Osteosarcoma.Front Oncol. 2020 Jun 2;10:769. doi: 10.3389/fonc.2020.00769. eCollection 2020. Front Oncol. 2020. PMID: 32582536 Free PMC article.
-
Investigating age‑induced differentially expressed genes and potential molecular mechanisms in osteosarcoma based on integrated bioinformatics analysis.Mol Med Rep. 2019 Apr;19(4):2729-2739. doi: 10.3892/mmr.2019.9912. Epub 2019 Jan 30. Mol Med Rep. 2019. PMID: 30720085 Free PMC article.
-
Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes.Clin Cancer Res. 2024 Dec 16;30(24):5630-5642. doi: 10.1158/1078-0432.CCR-24-1854. Clin Cancer Res. 2024. PMID: 39412757 Free PMC article.
-
Integration of single-cell RNA sequencing and bulk RNA sequencing to reveal an immunogenic cell death-related 5-gene panel as a prognostic model for osteosarcoma.Front Immunol. 2022 Sep 26;13:994034. doi: 10.3389/fimmu.2022.994034. eCollection 2022. Front Immunol. 2022. PMID: 36225939 Free PMC article.
References
-
- Wunder JS, Gokgoz N, Parkes R, Bull SB, Eskandarian S, Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey JH, Malkin D, Mangham DC, Rock MJ, Bell RS, Andrulis IL. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol. 2005;23:1483–1490. doi: 10.1200/JCO.2005.04.074. - DOI - PubMed
-
- Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, Ramsey KE, Antonescu CR, Chen W, Healey JH, Daluski A, Berens ME, Macdonald TJ, Gorlick R, Stephan DA. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005;65:1748–1754. doi: 10.1158/0008-5472.CAN-04-2463. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases